Market access and HTA strategy

Asc Academics has extensive experience in assisting companies with their application for reimbursement in Europe, creating a value story around the therapeutic added value and economic consequence of new health technology. We can fully develop and write reimbursement dossiers needed for HTA agencies and establish contact with key stakeholders to ensure a successful product launch.

Together with experienced partners, we excel in assessing the current and future situation in specific therapeutic areas, providing comprehensive advice to ensure the optimal reimbursement route. We provide full roadmaps and have a broad network that encompasses various stakeholders and clinical experts.

With an early Health Technology Assessment (HTA), we can support the identification of economically relevant endpoints of new health technologies since the clinical trial stage. Though an early HTA, we can assist you in go/no-go decisions, and help forming the basis for market access and reimbursement claims at a national level.

With an early pricing analysis, you can get a feel for the landscape of your competitors and position your product accordingly. Our team of market access experts have conducted many early pricing analyses aiding our clients to navigate through the hurdles of setting their pricing.

Reimbursement policy is characterized by a high speed of change and unique features in every country. Asc Academics has the expertise and network to provide an overview of reimbursement policy and national structures throughout countries in Europe to provide you with tailored advice for your product and market.